news – Page 78 – Medxy AI

Avutometinib Plus Defactinib: A Promising Treatment for Recurrent Low-Grade Serous Ovarian Cancer

By MedXY 09/08/2025

This phase II study demonstrates that the combination of avutometinib and defactinib offers significant clinical benefit with manageable safety in recurrent low-grade serous ovarian cancer, particularly in KRAS-mutant tumors.

Clinical Updates news Oncology Specialties

Xevinapant Fails to Improve Outcomes in Locally Advanced Head and Neck Cancer: Insights from the Phase III TrilynX Trial

By MedXY 09/08/2025

The TrilynX phase III study showed that adding xevinapant to platinum-based chemoradiotherapy did not improve event-free survival and was associated with worse overall survival and higher toxicity in unresected locally advanced squamous cell carcinoma of the head and neck.

Clinical Updates news Oncology Pathology & Lab Medicine

Revolutionizing Early Detection of Pancreatic Cancer: A cfDNA Fragmentomics and Machine Learning Model

By MedXY 09/08/2025

A new cell-free DNA fragmentomics model combined with machine learning achieves high accuracy for early pancreatic cancer detection, potentially improving patient outcomes through timely intervention.

Clinical Updates news Oncology Specialties

Bridging the Gap: Addressing Inconsistent Reporting of Venous and Arterial Thrombotic Events in Cancer Clinical Trials

By MedXY 09/08/2025

Venous and arterial thrombotic events in cancer patients are underreported in clinical trials, impairing risk assessment and prevention strategies. Uniform and comprehensive reporting is imperative to improve patient outcomes and guide therapeutic decisions.

Clinical Updates Family Medicine & Nutrition news

Rapamycin and Aging: Insights from the PEARL Trial on Safety and Healthspan Enhancements After One Year

By MedXY 09/08/2025

The PEARL trial demonstrates that low-dose, intermittent rapamycin is safe in healthy aging adults and improves lean tissue mass and pain in women, with additional benefits in emotional well-being and general health at lower doses.

Family Medicine & Nutrition news Urology

The Silent Decline: Understanding the Post-Pandemic Drop in Sexual Activity Among Americans

By MedXY 09/08/2025

A recent study highlights a historic decline in sexual activity in the U.S., driven by societal, psychological, and lifestyle factors, affecting all ages and calling for renewed attention to sexual health.

Clinical Updates Diabetes & Endocrinology news Oncology

Type 2 Diabetes and Colorectal Cancer: Immune Landscape Shapes Risk and Survival Outcomes

By MedXY 09/08/2025

Type 2 diabetes increases colorectal cancer risk and worsens survival, particularly in tumors with low immune cell infiltration, highlighting the interplay between metabolic and immune factors in cancer progression and prognosis.

Clinical Updates news OB/GYN & Women's Health Oncology

EPIK-O Trial Explores Alpelisib plus Olaparib Versus Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian Cancer Without BRCA Mutation

By MedXY 09/08/2025

The phase III EPIK-O trial showed no progression-free survival benefit of alpelisib plus olaparib over chemotherapy in BRCA wild-type platinum-resistant or refractory high-grade serous ovarian cancer, highlighting treatment challenges and biomarker insights.

Clinical Updates news Oncology

FDA Approval of Trastuzumab Deruxtecan: Advancing Treatment for HR-Positive HER2-Low and Ultralow Metastatic Breast Cancer

By MedXY 09/08/2025

Trastuzumab deruxtecan (T-DXd) gains FDA approval for HR-positive, HER2-low and HER2-ultralow unresectable or metastatic breast cancer after endocrine therapy progression, offering significant progression-free survival benefits over chemotherapy.

Clinical Updates Family Medicine & Nutrition news

Timing Matters: Determining the Optimal Duration of Supervised Exercise for Meaningful Improvements in Peripheral Artery Disease

By MedXY 09/08/2025

A supervised treadmill exercise program lasting over 6 weeks is essential to achieve significant walking improvements in peripheral artery disease, with peak patient-reported benefits observed at 12 weeks but diminishing by 26 weeks.

Cardiology news Pathology & Lab Medicine

Serum Carboxymethyl-Lysine and Its Prospective Associations with Heart Failure and Atrial Fibrillation in Older Adults: Insights from the Cardiovascular Health Study

By MedXY 09/08/2025

Serum advanced glycation end-product carboxymethyl-lysine (CML) is linked to higher risks of heart failure and atrial fibrillation in older adults, highlighting potential therapeutic targets against AGE-related cardiac dysfunction.

Family Medicine & Nutrition news Oncology

10 Habits That Cancer Cells Fear: Building Your Body’s Natural Defense

By MedXY 09/08/2025

Explore ten evidence-based lifestyle habits that significantly reduce cancer risk and empower your body’s natural defenses against cancer development.

Diabetes & Endocrinology news

Oral Semaglutide Demonstrates Significant Weight Loss Efficacy in East Asian Adults with Overweight or Obesity: Insights from the OASIS 2 Trial

By MedXY 09/08/2025

The OASIS 2 trial shows oral semaglutide 50 mg significantly reduces body weight in East Asian adults with overweight or obesity, with or without type 2 diabetes, offering a promising therapeutic option with manageable safety profile.

Clinical Updates Diabetes & Endocrinology news Specialties

Consistent Improvement in Walking Function Across Diabetes Profiles with Semaglutide in Peripheral Artery Disease: Lessons from the STRIDE Trial

By MedXY 09/07/2025

The STRIDE trial demonstrates that once-weekly semaglutide significantly enhances walking capacity in patients with symptomatic peripheral artery disease and type 2 diabetes, irrespective of baseline diabetes duration, BMI, HbA1c levels, or diabetes medication use.

Clinical Updates Diabetes & Endocrinology news

Advancing Obesity Management: Once-Monthly Maridebart Cafraglutide Demonstrates Significant Weight Loss Efficacy

By MedXY 09/07/2025

Maridebart cafraglutide, a novel once-monthly peptide-antibody conjugate, significantly reduces body weight in individuals with obesity, with and without type 2 diabetes, offering a new therapeutic option based on phase 2 trial results.

Dermatology Infectious Diseases news

One Dose or Three? Reevaluating Benzathine Penicillin G Therapy for Early Syphilis

By MedXY 09/07/2025

A recent multicenter trial demonstrates that a single dose of benzathine penicillin G is noninferior to three doses in treating early syphilis, including patients with HIV, simplifying management and reducing adverse effects.

Cardiology news Specialties

Obicetrapib: A Promising Advance in LDL Cholesterol Lowering for High Cardiovascular Risk Patients

By MedXY 09/07/2025

Obicetrapib significantly reduces LDL cholesterol by nearly 30% in high-risk cardiovascular patients on maximal lipid therapy, with a safety profile comparable to placebo, representing a potential novel agent in managing familial hypercholesterolemia and atherosclerotic cardiovascular disease.

Clinical Updates Diabetes & Endocrinology news Specialties

Injectable GLP-1 Use Soars Among US Adults with Diabetes: Trends and Clinical Implications

By MedXY 09/07/2025

Nearly 1 in 4 US adults with diabetes used injectable GLP-1 receptor agonists in 2024, reflecting rising adoption for glycemic control and obesity management with notable demographic disparities.

Critical Care news Specialties

Top Ten Essential Tips for Palliative Care Clinicians Consulting in Intensive Care Units

By MedXY 09/07/2025

This article provides ten practical tips for palliative care clinicians to optimize consultation effectiveness in ICUs, emphasizing collaboration, communication, cultural respect, conflict resolution, and transition planning to improve patient and family outcomes.

Clinical Updates news OB/GYN & Women's Health Specialties

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review

By MedXY 09/07/2025

This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone therapy duration, global experiences, breast cancer management, dementia risk, and personalized hormone therapy safety.